Please use this identifier to cite or link to this item: https://doi.org/10.1186/s13045-015-0163-z
Title: Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: A clinicopathologic analysis of 61 patients
Authors: Loghavi, S
Alayed, K
Aladily, T.N
Zuo, Z
Ng, S.-B 
Tang, G
Hu, S
Yin, C.C
Miranda, R.N
Medeiros, L.J
Khoury, J.D
Keywords: cyclophosphamide
dexamethasone
doxorubicin
etoposide
prednisone
vincristine
antineoplastic agent
abdominal pain
adult
age distribution
aged
Article
cancer chemotherapy
cancer prognosis
cancer staging
cancer survival
carcinogenesis
clinical evaluation
cohort analysis
colorimetry
controlled study
correlational study
cytogenetics
diarrhea
epistaxis
Epstein Barr virus
Epstein Barr virus infection
event free survival
female
fluorescence in situ hybridization
follow up
gastrointestinal symptom
gene overexpression
gene rearrangement
health impact assessment
histopathology
human
Human immunodeficiency virus infection
human tissue
immunocompromised patient
immunophenotyping
major clinical study
male
nose ulcer
oncogene myc
outcome assessment
overall survival
plasmablastic lymphoma
rectum hemorrhage
rhinorrhea
sinusitis
very elderly
virus detection
age
cancer staging
complication
Epstein Barr virus infection
genetics
middle aged
pathology
plasmablastic lymphoma
treatment outcome
young adult
Adult
Age Factors
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Cohort Studies
Epstein-Barr Virus Infections
Female
Humans
Male
Middle Aged
Neoplasm Staging
Plasmablastic Lymphoma
Treatment Outcome
Young Adult
Issue Date: 2015
Citation: Loghavi, S, Alayed, K, Aladily, T.N, Zuo, Z, Ng, S.-B, Tang, G, Hu, S, Yin, C.C, Miranda, R.N, Medeiros, L.J, Khoury, J.D (2015). Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: A clinicopathologic analysis of 61 patients. Journal of Hematology and Oncology 8 (1) : 65. ScholarBank@NUS Repository. https://doi.org/10.1186/s13045-015-0163-z
Rights: Attribution 4.0 International
Abstract: Background: Plasmablastic lymphoma (PBL) is a rare aggressive neoplasm with lymphoid and plasmacytic differentiation that is commonly associated with immunodeficiency and an unfavorable prognosis. Clinicopathologic features have been largely derived from cases reports and small series with limited outcome analyses. Patients and methods: The demographic, clinicopathologic features, and clinical outcomes of a cohort of 61 patients with PBL were reviewed and analyzed. Results: Patients had a median age of 49 years (range 21-83 years) and most (49/61; 80 %) were men. Human immunodeficiency virus (HIV) status was available for 50 patients: 20 were HIV-positive and 30 HIV-negative. Twenty-three patients were immunocompetent. Abdominal/gastrointestinal complaints were the most common presenting symptoms, reported in 14 of 47 (30 %) of patients. At presentation, 24 of 43 (56 %) patients had stage III or IV disease. Epstein-Barr virus (EBV) was detected in 40 of 57 (70 %) cases. MYC rearrangement was identified in 10/15 (67 %) cases assessed, and MYC overexpression was seen in all cases assessed regardless of MYC rearrangement status. HIV-positive patients were significantly younger than those who were HIV-negative (median 42 vs. 58 years; p∈=∈0.006). HIV-positive patients were also significantly more likely to have EBV-positive disease compared with HIV-negative patients (19/19, 100 % vs. 15/29, 52 %; p∈=∈0.002). Patients who received CHOP chemotherapy tended to have better overall survival (OS) compared with those who received hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) (p∈=∈0.078). HIV status had no impact on OS. Patients with EBV-positive PBL had a better event-free survival (EFS) (p∈=∈0.047) but not OS (p∈=∈0.306). Notably, OS was adversely impacted by age ge;50 years (p∈=∈0.013), stage III or IV disease (p∈=∈<0.001), and lymph node involvement (p∈=∈0.008). Conclusions: The most significant prognostic parameters in patients with PBL are age, stage, and, to a lesser extent, EBV status. In this study, two-thirds of PBL cases assessed were associated with MYC rearrangement and all showed MYC overexpression. © 2015 Loghavi et al.
Source Title: Journal of Hematology and Oncology
URI: https://scholarbank.nus.edu.sg/handle/10635/180909
ISSN: 17568722
DOI: 10.1186/s13045-015-0163-z
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_s13045-015-0163-z.pdf2.03 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons